- South Africa
- Our innovation
- Focus areas
- Neuroscience
Neuroscience
Despite advancements in neuroscience over the past 60 years, unmet need persists for people living with disorders of the nervous system. However, there has been significant progress in understanding and treating these diseases. We never stop pushing the boundaries of what is possible to the benefit of the patients.
We are building a world-class pipeline driven by innovation that we hope will lead to transformative therapies for a diverse population of patients with neuropsychiatric, neurodegenerative and neurological disorders. Through scientific advancements, a broad range of expertise, and strategic partnerships, we aim to fundamentally change how these disorders are treated and make a real difference, not just for patients, but also for society.
We are building a world-class pipeline driven by innovation that we hope will lead to transformative therapies for a diverse population of patients with neuropsychiatric, neurodegenerative and neurological disorders. Through scientific advancements, a broad range of expertise, and strategic partnerships, we aim to fundamentally change how these disorders are treated and make a real difference, not just for patients, but also for society.
Approximately one per cent of the population is affected by schizophrenia. Schizophrenia is characterized by two distinct sets of symptoms, positive symptoms and negative symptoms. These can include false beliefs, confused thinking, hallucinations, reduced social engagement and affective symptoms. The first episode usually occurs in late teens to early twenties in men, and late twenties in females. [1]
You are now leaving J&J Innovative Medicine
The site you’re being redirected to is a branded pharmaceutical website. Please click below to continue to that site.
Transparency
We are committed to transparency and integrity in our interactions with healthcare professionals and organizations. This page provides detailed reports on our Transfers of Value (ToV), reflecting our dedication to compliance and fostering trust within the medical community.
References:
[1] World Health Organisation. Schizophrenia. https://www.who.int/news-room/fact-sheets/detail/schizophrenia.
CP-497732 | January 2025